Cardiorenal

How Long Should DAPT Continue After PCI?

Quick answer

For stable coronary disease post-PCI, 1–3 months of DAPT followed by P2Y12 monotherapy is non-inferior to 12 months for ischemic events and reduces bleeding. For ACS, 12 months remains the default, but MASTER DAPT and TWILIGHT support 1–3 months of DAPT followed by ticagrelor or clopidogrel monotherapy in high-bleed-risk patients.

Evidence review

Pivotal trials, effect sizes, and the populations they studied. PubMed identifiers link directly to the source.

TWILIGHT (2019)

PMID 31556978

7,119 high-risk PCI patients, 65% ACS

After 3 months DAPT, ticagrelor monotherapy vs ticagrelor + aspirin reduced BARC 2/3/5 bleeding 44% (HR 0.56, 95% CI 0.45–0.68); no difference in ischemic outcomes.

MASTER DAPT (2021)

PMID 34449185

4,434 high-bleed-risk PCI patients with Ultimaster stent

1 month DAPT then SAPT non-inferior to ≥3 months DAPT for NACE (HR 0.97); reduced major/clinically relevant bleeding 33% (HR 0.67).

STOPDAPT-2 ACS (2022)

PMID 35234821

4,169 ACS patients

1–2 months DAPT then clopidogrel monotherapy did not meet non-inferiority for ischemic events (HR 1.50); more MI. DAPT ≥3 months preferred in ACS.

Practical decision algorithm

IfThen
Stable CAD, standard bleed riskDAPT 6 months (aspirin + P2Y12), then aspirin indefinitely. Consider 1–3 months then P2Y12 monotherapy if high bleed risk.
Stable CAD, high bleed risk (ARC-HBR positive)1–3 months DAPT, then P2Y12 monotherapy (clopidogrel or ticagrelor).
ACS, standard bleed riskDAPT 12 months (aspirin + ticagrelor/prasugrel preferred), then aspirin.
ACS, high bleed riskDAPT 3 months then ticagrelor monotherapy (TWILIGHT, MASTER DAPT strategy).
Post-PCI patient requiring chronic OAC (AFib, VTE)Triple therapy ≤1 week then DOAC + P2Y12 (clopidogrel) 6–12 months; drop P2Y12 thereafter (AUGUSTUS).

Guideline position

2023 ACC/AHA/SCAI chronic coronary disease guideline: 6 months DAPT post-PCI for stable CAD (Class 1); 1–3 months acceptable in high bleed risk. 2023 ESC ACS guideline: 12 months DAPT default for ACS; shortening to 3 months reasonable in high-bleed-risk (Class 2a).

Contraindications and cautions

  • Active major bleeding
  • Intracranial hemorrhage within 6 months (ticagrelor/prasugrel contraindicated)
  • Prior stroke/TIA (prasugrel contraindicated)
  • Severe hepatic impairment (ticagrelor)
  • Platelet count <50,000

Frequently asked questions

Is prasugrel or ticagrelor preferred over clopidogrel?
In ACS, yes — ticagrelor and prasugrel reduce ischemic events compared with clopidogrel (PLATO, TRITON). ISAR-REACT 5 favored prasugrel in invasive ACS. Avoid prasugrel in prior stroke, age ≥75, or weight <60 kg.
How do I identify ARC-HBR?
Major criteria: eGFR <30, active cancer, Hb <11, prior bleeding requiring hospitalization. One major or two minor criteria = high bleed risk. Calculators are in most EHRs.
Can I de-escalate from ticagrelor to clopidogrel?
Yes. TOPIC and TALOS-AMI supported de-escalation to clopidogrel after 1 month of ACS DAPT with ticagrelor, reducing bleeding without raising ischemic events.
What about aspirin monotherapy vs P2Y12 monotherapy long-term?
HOST-EXAM showed clopidogrel monotherapy superior to aspirin after completion of DAPT for combined ischemic/bleeding outcomes. Reasonable alternative, especially in PCI patients.
When can I stop DAPT for elective surgery?
Hold P2Y12 5–7 days pre-op (clopidogrel/ticagrelor) or 7 days (prasugrel). Continue aspirin when possible. Delay non-urgent surgery for 1 month post-BMS, 3 months post-DES for stable CAD, and 6 months for ACS.

Further reading

Clinical Reasoning

Acute Coronary Syndrome: STEMI and NSTEMI Management Updates for 2026

Evidence-Based Medicine

Atrial Fibrillation: Rate vs Rhythm Control in 2026 — EAST-AFNET 4 and Beyond

Clinical Reasoning

Peripheral Artery Disease: Revascularization vs Medical Therapy and VOYAGER PAD Data

Back to all decision points